Yesterday it was reported that the Chief Innovation Officer of SAGE Therapeutics (SAGE), Jeffrey Jonas, exercised options to buy 1,800 SAGE shares at $0.45 a share, for a total transaction value of $810.
Following Jeffrey Jonas’ last SAGE Buy transaction on December 10, 2019, the stock climbed by 17.2%. This recent transaction increases Jeffrey Jonas’ holding in the company by 3.3% to a total of $4.54 million.
See today’s analyst top recommended stocks >>
The company has a one-year high of $98.39 and a one-year low of $25.01. Currently, SAGE Therapeutics has an average volume of 489.46K. SAGE’s market cap is $5.16 billion and the company has a P/E ratio of -8.70.
15 different firms, including BMO Capital and Merrill Lynch, currently also have a Buy rating on the stock. Based on 19 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $88.88, reflecting a -8.9% downside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
